中国药企出海报告（英）.docx

NAVIGATINGG1.OBA1.MARKETSCO-PRODUCEDBYPharmcubeiDeal三命PHARMCUBEEmpowerBiopharmaInnovationAccelerateDecision-makingFoundedin2015,Pharmcubestrivestoreconstructpharmaceuticaldata,bridgetheinformationgap,andthoroughlyempowerinnovation.Byleveragingdataacrossthefulllife-cycleofpharmaceuticalproductsplusscalableandhighlycompatibleAltechnology,Pharmcubehassuccessfullylaunchedovertenenterprise-leveldataproducts,serving1,000+leadingpharmaceuticalcompaniesandinvestmentinstitutions.Wealsoprovideyouwithmediaandconsultingservicesthatfacilitateyourstrategicplanninganddecision-makingandpromotetheinnovationandtransformationofthepharmaceuticalindustry.OurIndustryInfluenceOurtrustworthydataandconstantly-improvingservicehavewonclient,sheart.800,000+Millionsof1000+7÷years1.eadingpharma.AccumuUttionoSubscriboraSearchespermonthcompaniesandinstitutions,choicepharmaceuticaldataWeAreGrowingWeteamupwithtoptalents.Over56%masterorPh.Dholders,andmorethan60%topuniversitygraduates(suchasPekingUniversity,TsinghuaUniversity,FudanUniversityorShanghaiJiaoTongUniversity),around10%ofthemreceiveeducationinoverseasuniversities.Ourteamofdataspecialistshavenotjustexperiencebutalsothespirittoinnovate.PharmcubeNeXtBiOPharmTM-Timely,accurateandreliableintelligenceonglobalnewdrugs"IntroducingNextBiopharm,acutting-edgedatabasemeticulouslycraftedandlaunchedbyPharmcube,designedspecificallytospotlightglobalnewdrugswithunparalleledcoverageintheChinesemarket.Thisplatformseamlesslyintegratesandstandardizesawealthofinformation,includingpatents,literature,clinicaltrials,news,deals,andmarketingdata,providingacomprehensiveoverviewofeverynovelmoleculeworldwide.AsaproudmemberofthePharmcubefamily,NeXtBiOPharmTMTMiswelllinkedwithotherofferingssuchasNextPat®,PharmaGO®,MedAlpha®,etc.,ensuringarobustconnectivitythatcaterstothediverseneedsofthepharmaceuticalMini-programClinicalDataKnowledgeCardsNewsandRePOrtSTranslationalScienceCompetitiveIntelligenceDiseaseAnalysisBusinessAnalysisdrugsAnalysisTargetA呵ysisAlCapabilities:Automatedprediction/Auto-FlownnntafinnHumanIntelligence:InsightfulAnalysisDatamonitoringCleansingMndardizationindustryandinvestorsalike.WebDal三三iDealsVDREmpowers75%ofOut-licensingDealsAsBDtransactionsbecomemorefrequentandactive,iDealsSolutionsprovidesacomprehensiveVDRsolution,whichisasapowerfulassistantforBDtransactionsinthebiopharmaceuticalindustry:thevirtualdataroom(VDR)becomesanindispensabletoolforinformationinteractionatatimewhendistancesmakeinformationinteractioninconvenientandtheprocessofbuildingtrustverylengthy.Itsimplifiestheprocessofsharingandmanagingsensitiveandconfidentialdocuments.Itsfinancial-gradedocumentsecuritysolutionensuresthatthecompany'sconfidentialdocumentsmeetthemoststringentcompliancerequirementsinBDtransactionusagescenarios.EmpowerstheentireprocessofcorporateBDtransactions,includingprotectingdatasecurity,supportingduediligenceandauditing,enhancingtransactionefficiency,improvingtransactiontransparency,andreflectinganefficientprofessionalimage.ContactUsPharmcubeContactus：AboutProduct/ServicedaisiweiAfter-SalessanyunanForMediaCollaborationzhangxiaoyiiDealsContactus：Trialrequest:iohn.vuaridealscogcomWWWCONTENTSPARTONEFollowthetrendofthetimesFactorscompellingChinesepharmaceuticalcompaniestogoglobal7PARTTWOInsightsontransactionsScenariosanddataofChinesepharmaceuticalcompaniesgoingoverseas18PARTTHREEEarlymoversIn-depthanalysisoftypicalcases24PARTFOURData-baseddecision-makingApplicationofdatainscreeningoverseasopportunities41PARTONEFactorsCompellingChinesePharmaceuticalCompaniestoGoGlobalIInrecentyears,Chinesepharmaceuticalcompanieshavebeentakingtheinitiativetotapintotheglobalmarketasaresultofanumberoffactors.lntensecompetitionwithintheChinesemarketisdrivingcompaniestoseekoutopportunitiesforsurvivalspaceinoverseasmarkets.Themedicalinsurancepaymentreformandrestrictedhospitalaccesshavesqueezedtheprofitmarginsofinnovativedrugs.Additionally,somesectorswithintheindustryhavewitnessedfiercecompetitionsurroundinghomogeneousproducts.Consequently,someChinesecompaniesareturningtotheglobalmarketfornewgrowthspaceandstrongerprofitability.IFacedwithfinancialchallenges,manycompaniesarechoosingtoseekinvestmentandcollaboratewithothersinordertostayinbusiness.Thepharmaceuticalindustryisexperiencingdownwardpressure,withmostcompanieshavingdifficultyinfundingandcashflows.Inlightofthis,relinquishingaportionoftheirinterestsintheoverseasmarketinreturnforcashandsubsequentfundingpresentsanadvantageoussurvivalstrategyformostcompanies.IWithgrowingstrengthinR&Dofnewdrugs,Chinesecompaniesshowstrongerglobalcompetitiveness.Asmoretale